What We're Reading: Page 313
Industry reads hand-picked by our editors
Sep 16, 2016
-
Bloomberg
Valeant heart drug discounts haven't materialized, hospitals say
-
The Street
Gilead's pipeline, maligned by investors, still packed with 4Q clinical trial readouts
-
New York Times
EpiPen maker Mylan quietly steers efforts to protect its price
-
Washington Post
Turmoil at federal agency threatens oversight of biomedical research
Sep 15, 2016
Sep 14, 2016
-
Financial Times
Takeda earmarks $15bn for US pharmaceutical acquisitions
-
Forbes
How GlaxoSmithKline took its medicine
-
The Street
Sarepta drug critic departs FDA, raising hope for approval
-
Wall Street Journal
EpiPen maker dispenses outsize pay
-
Regulatory Focus
FDA to hold one advisory committee for each initial biosimilar
Sep 13, 2016
-
Stat
Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
-
Wall Street Journal
High cost of new hepatitis C drugs strains prison budgets, locks many out of cure
-
Forbes
Celgene data offer a Rorschach test to Wall Street
-
Triangle Business Journal
IMS Health to raise $1.5B in connection with Quintiles buy
Sep 12, 2016
Sep 09, 2016
-
Bloomberg
Bayer said to explore sale of $1.1 billion dermatology business
-
Stat
Bold claim of multiple sclerosis gene discovery comes under withering attack
-
New York Times
A push to lower drug prices that hit insurers and employers the hardest
-
Reuters
Statins' benefits understated and harms exaggerated, scientists warn
Previous
